Lenvatinib as second-line treatment in patients with unresectable hepatocellular carcinoma: A retrospective analysis
Lenvatinib
Second line treatment
DOI:
10.3389/fonc.2022.1003426
Publication Date:
2022-11-22T07:25:00Z
AUTHORS (7)
ABSTRACT
The purpose of this study is to determine the efficacy and safety lenvatinib as second-line therapy in Chinese patients with unresectable hepatocellular carcinoma (HCC). We performed a retrospective analysis HCC who received treatment at three institutions from November 2018 February 2022. Demographic clinicopathologic characteristics, data on regimens were obtained medical records. Tumor response was evaluated every 4-6 weeks by modified Response Evaluation Criteria Solid Tumors (mRECIST). In total, 50 enrolled study. objective rate (ORR) 18.0% disease control (DCR) 74.0%, respectively. duration (DoR) 6.0 months. median progression-free survival (PFS) overall (OS) 5.0 8.5 months, Patients ICIs combined anti-angiogenic inhibitors first-line therapy, achieving CR/PR PFS≥6months had higher DCR. Univariate multivariate showed that AFP (ng/ml)<400, absence extrahepatic metastasis, Child-Pugh A, tumor number<3, independent factors favorable PFS. significantly associated longer OS. Multivariate prognostic majority AEs grade 1-2, reversible. Grade 3/4 occurred 12 (24.0%) mostly connected hand-foot skin reactions (10.0%), 10 dose reductions. Two toxicity-related interruptions attributed 3 reaction, 4 proteinuria, This confirms after progression sorafenib or inhibitors.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (27)
CITATIONS (3)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....